BUSPAR Drug Patent Profile

Which patents cover Buspar, and when can generic versions of Buspar launch?

Buspar is a drug marketed by Bristol Myers Squibb and is included in two NDAs.

The generic ingredient in BUSPAR is buspirone hydrochloride. There are nineteen drug master file entries for this compound. Forty-seven suppliers are listed for this compound. Additional details are available on the buspirone hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Buspar

A generic version of BUSPAR was approved as buspirone hydrochloride by IMPAX LABS INC on March 28^th, 2001.

Summary for BUSPAR

US Patents:	0
Applicants:	1
NDAs:	2
Raw Ingredient (Bulk) Api Vendors:	95
Clinical Trials:	20
Patent Applications:	765
DailyMed Link:	BUSPAR at DailyMed

Recent Clinical Trials for BUSPAR

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Spaulding Rehabilitation Hospital	Phase 2
University of Louisville	Early Phase 1
National Institute of Neurological Disorders and Stroke (NINDS)	Early Phase 1

See all BUSPAR clinical trials

US Patents and Regulatory Information for BUSPAR

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bristol Myers Squibb	BUSPAR	buspirone hydrochloride	CAPSULE;ORAL	021190-001	Dec 20, 2000		DISCN	Yes	No
Bristol Myers Squibb	BUSPAR	buspirone hydrochloride	TABLET;ORAL	018731-003	Apr 22, 1996		DISCN	Yes	No
Bristol Myers Squibb	BUSPAR	buspirone hydrochloride	CAPSULE;ORAL	021190-004	Dec 20, 2000		DISCN	Yes	No
Bristol Myers Squibb	BUSPAR	buspirone hydrochloride	TABLET;ORAL	018731-004	Apr 22, 1996		DISCN	Yes	No
Bristol Myers Squibb	BUSPAR	buspirone hydrochloride	CAPSULE;ORAL	021190-002	Dec 20, 2000		DISCN	Yes	No

Expired US Patents for BUSPAR

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Bristol Myers Squibb	BUSPAR	buspirone hydrochloride	TABLET;ORAL	018731-002	Sep 29, 1986
Bristol Myers Squibb	BUSPAR	buspirone hydrochloride	TABLET;ORAL	018731-003	Apr 22, 1996
Bristol Myers Squibb	BUSPAR	buspirone hydrochloride	TABLET;ORAL	018731-001	Sep 29, 1986
Bristol Myers Squibb	BUSPAR	buspirone hydrochloride	TABLET;ORAL	018731-002	Sep 29, 1986
Bristol Myers Squibb	BUSPAR	buspirone hydrochloride	TABLET;ORAL	018731-004	Apr 22, 1996

International Patents for BUSPAR

See the table below for patents covering BUSPAR around the world.

Country	Patent Number	Title	Estimated Expiration
Belgium	759371
Switzerland	552607	VERFAHREN ZUR HERSTELLUNG VON AZASPIROALKANDION-DERIVATEN.
Switzerland	552608	VERFAHREN ZUR HERSTELLUNG VON AZASPIROALKANDION-DERIVATEN.
Cyprus	886	HETEROCYCLIC AZASPIROALKANEDIONES
Germany	2057845

Buspar (buspirone) market dynamics and financial trajectory (US-focused)

Last updated: June 3, 2026

Executive summary: Buspar (buspirone hydrochloride) has a mature, low-growth US market shaped by long patent/market exclusivity history, widespread generic availability, and limited brand-specific price and share upside. The financial trajectory is driven primarily by (1) generic price erosion and channel stocking dynamics, (2) prescription volume trends in anxiety/panic indications, and (3) payer formulary positioning for generic buspirone versus branded and off-formulary alternatives. Brand-financial upside is capped by generic competition, while ongoing demand stability is the main support.

Why does Buspar have limited growth versus generics in the US market?

Buspar is an older small-molecule anxiolytic (buspirone). In the US, market structure is dominated by generics once brand exclusivity ends. As a result, the brand’s sales dynamics typically show: share erosion, price compression, and increased sensitivity to payer preferences for low-cost buspirone SKUs.

What generic entry risks exist for Buspar?

For branded Buspar, the generic entry risk is no longer a “future event” in the normal sense; generic buspirone is already established and scaled. The ongoing risk is economic: further price declines, distributor pull-through shifts, and payer contract tightening that concentrates volume in the lowest-cost NDCs.

What drives payer and pharmacy behavior for buspirone?

Key determinants are usually:

• Wholesale acquisition cost convergence across generic manufacturers
• Formulary tier placement (generic tier with preferred rebates)
• PBM contracting that favors specific manufacturers
• Pharmacy switching driven by reimbursement and inventory

How do anxiety and panic prescription trends affect Buspar revenue?

Buspirone is used for generalized anxiety disorder (GAD) and anxiety associated with depression, and it is also used off-label in clinical practice. Revenue trajectories in mature markets track:

• Diagnosed prevalence and treatment penetration
• Competition from other first-line anxiolytics (SSRIs/SNRIs, benzodiazepines where appropriate, and alternatives)
• Medication adherence patterns (buspirone is not a rapid-onset benzodiazepine substitute)
• Clinical guideline adoption and prescribing habits

What substitution patterns change buspirone demand?

Common substitution dynamics include:

• Switching from buspirone to an SSRI/SNRI after inadequate symptom control
• Temporary benzodiazepine augmentation (if used) during early onset phases
• Longer-term preference shifts toward agents with lower perceived titration burden

When does Buspar lose exclusivity and why does it matter for financial trajectory?

Buspar is not governed by a modern exclusivity ramp like newer brands. The core financial driver is that brand exclusivity is long expired, so revenue is constrained by entrenched generic competition. The “timeline” effect manifests as:

• Early phase: brand share and pricing power
• Middle phase: generic share capture and price compression
• Current phase: stable but limited brand volume, with any brand growth primarily from non-price factors (patient familiarity, prescriber inertia, payer exceptions) rather than market expansion.

What patents protect buspirone (Buspar) and how does that translate to revenue?

In a mature product, patent protection mainly affects legal freedom to use specific process/formulation claims rather than blocking generic supply at the molecule level. For business outcomes, what matters is whether any evergreening claims remain enforceable for specific dosage forms, strengths, or manufacturing methods.

Do formulation and method patents change the competitive landscape?

For older small molecules, such patents can create narrow carve-outs (specific release characteristics, stability improvements, or manufacturing steps) but they typically do not recreate brand-level exclusivity across the whole label. The net effect on brand economics is usually modest: it may limit certain generic variants rather than stop generic buspirone supply.

What is the Orange Book status of Buspar and what does it imply for generic pricing?

Orange Book listings for older small molecules generally show expired patents and current listed references. When patents and exclusivities are expired, the typical outcome is:

• Multiple ANDA-approved generic manufacturers
• Increased price competition
• Greater PBM pressure toward low-cost preferred NDCs

How does Orange Book status influence contract behavior?

PBMs and large payers negotiate rebates using:

• Manufacturer concentration and reliability
• Expected supply stability
• Contracted AWP to net price deltas Once patents are fully cleared, the contract cycle becomes price-led rather than exclusivity-led.

How strong is the patent estate for buspirone-based anxiety products?

For an older brand, the practical “strength” metric for deal and litigation purposes is whether there are any still-in-force, relevant claims that can block a specific ANDA or a specific formulation. In most established cases, remaining claims are fewer and narrower, reducing the chance of a broad injunction against generic buspirone products.

What does this mean for litigation and settlements?

Litigation outcomes in mature buspirone often do not prevent generic entry at a category level because:

• Molecule-level exclusivity is long gone
• Residual claims, if any, often map to a narrower product design space
• Settlements usually reflect risk-sharing on narrow claim issues rather than long delays

What generic entry scenarios affect the Buspar brand today?

Scenario categories that can still impact brand financials even after broad generic entry include:

• Further net price erosion from additional low-cost entrants
• Channel re-contracting after ASP/AWP thresholds trigger renegotiations
• NDC-level volume shifts as pharmacies switch among preferred manufacturers
• Short supply disruptions at specific generic sites that temporarily benefit whichever product remains available

How does Buspar compare with competing anxiety drugs economically?

From a market dynamics view, buspirone competes with:

• SSRIs/SNRIs (often stronger long-term efficacy perception, but different onset timelines)
• Benzodiazepines (rapid symptom relief, but tighter controlled-substance and dependence concerns)
• Other anxiolytics/augmentation strategies used by prescribers

Why does buspirone’s dosing profile matter?

Buspirone is generally not a same-day rescue medication. That shifts patient selection and prescriber behavior. Economic outcomes follow: when prescribers seek immediate relief, buspirone often loses to alternatives, limiting prescription growth even when price is attractive.

What FDA regulatory pathway history implies for Buspar supply and competition?

Buspirone is an established oral small molecule. The current competitive state depends on:

• ANDA market depth across strengths and dosage forms
• Bioequivalence and labeling parity across generics
• Manufacturing capacity that sustains supply during demand fluctuations

Are there REMS or special regulatory constraints?

Buspirone does not typically face the same high-friction regulatory programs as some higher-risk therapeutics. That reduces barriers to multiple generic approvals, reinforcing price competition.

Commercial outlook: what financial trajectory best describes mature Buspar economics?

For a mature, generic-dominated brand, the base-case financial trajectory is usually:

• Flat to low single-digit decline in brand value absent brand-specific protected niches
• Main swings driven by net pricing, reimbursement policy changes, and pharmacy contracting shifts
• Volatility tied more to competitive pricing than to clinical uptake

Revenue drivers to watch (business metrics)

• Net price per prescription trend for the branded product versus generic benchmarks
• Prescriber switching and share-of-voice changes among anxiety treatments
• PBM formulary changes for generic buspirone manufacturers
• Channel inventory behavior (stocking and destocking cycles)

Key takeaways

• Buspar’s financial trajectory is constrained by mature generic competition and payer-led price compression.
• Market dynamics are dominated by generic buspirone economics, not by brand exclusivity.
• Prescription volume trends in anxiety management drive the upper bound, while substitution to SSRIs/SNRIs and other anxiolytics limits upside.
• Ongoing brand impact is mostly NDC-level, payer-contract driven and sensitive to generics’ lowest-price positioning.

FAQs

1. How do PBM formulary tiering and rebates typically affect generic buspirone versus Buspar brand pricing?
2. What disease-state and guideline shifts most influence US prescribing of buspirone for generalized anxiety disorder?
3. Do generic supply disruptions for buspirone ever create temporary brand share gains for Buspar?
4. How does buspirone’s onset profile affect patient selection compared with benzodiazepines and SSRI/SNRI initiation strategies?
5. Which competitive metrics (ASP, net price, script share) best predict Buspar revenue direction in a generic-saturated category?

References

1. FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. US FDA.
2. FDA. Drug Approval Reports and ANDA approval information for buspirone hydrochloride generics. US FDA.

DrugChatter Q&A for BUSPAR

Buspar cost without insurance?
What class of drug is buspar?
Why was buspar taken off the market?
Why does buspar take so long to work?
Is buspar still on the market?